Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Genomic Health, Inc.    GHDX   US37244C1018

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/24/2015 02/25/2015 02/26/2015 02/27/2015 03/02/2015 Date
30.28(c) 31.05(c) 31.05(c) 30.4(c) 31.1(c) Last
80 700 49 916 98 687 117 419 139 275 Volume
-2.26% +2.54% 0.00% -2.09% +2.30% Change
More quotes
Company
Genomic Health, Inc. is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions.The company has a robust pipeline focused on developing tests to optimize the treatment of renal cell cancers, as well as additional treatment decisions in... 
More about the company
Surperformance© ratings of Genomic Health, Inc.
Trading Rating : Investor Rating :
More Ratings
Chart GENOMIC HEALTH, INC.
Duration : Period :
Genomic Health, Inc. Technical Analysis Chart | GHDX | US37244C1018 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 299 M
EBIT 2015 -19,9 M
Net income 2015 -19,9 M
Debt 2015 112 M
Yield 2015 -
Sales 2016 342 M
EBIT 2016 3,11 M
Net income 2016 1,94 M
Debt 2016 144 M
Yield 2016 -
PER 2015 -
PER 2016 410,29
EV / Sales 2015 3,67x
EV / Sales 2016 3,31x
Capitalization 987 M
More Financials
Latest news on GENOMIC HEALTH, INC.
02/20 GENOMIC HEALTH : Change in Directors or Principal Officers (form 8-K)
02/16 GENOMIC HEALTH : Announces Year-End 2014 Financial Results, Provides 2015 Financ..
02/15 GENOMIC HEALTH : Recaps Year-End 2014 Financial Results
02/13 GENOMIC HEALTH : Reports Year-End 2014 Financial Results
02/11 GENOMIC HEALTH : Following NICE's Exclusive Recommendation, NHS England Agrees t..
02/11 GENOMIC HEALTH : Announces Year-End 2014 Financial Results
02/10 GENOMIC HEALTH : reports 4Q loss
02/10 GENOMIC HEALTH : Results of Operations and Financial Condition, Financial Statem..
More news
Sector news Biotechnology & Medical Research - NEC
03/02 PUMA BIOTECHNOLOGY : Biotech reports 4Q loss
03/02 PUMA BIOTECHNOLOGY : Reports Fourth Quarter and Full Year 2014 Financial Results
03/02 ACTELION : Selexipag (Uptravi) data in pulmonary arterial hypertension to be pre..
Plus d'actualités du secteur Biotechnology & Medical Research - NEC


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF